GleamWall
中文EN

BDTX Black Diamond Therapeutics, Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1701541 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-100.0%
TTM net income YoY-305.0%
TTM EPS YoY-305.4%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-41.1%
ROA-32.3%
ROIC (approx.)-49.8%
Asset turnover0.00x

Leverage & solvency

Liabilities / assets23.8%
Debt / equity0.00x
Current ratio6.92x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.76x
Accruals ratio-7.9%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$0$0$0$0$0$0$70.00M$0
R&D expense$6.97M$7.39M$7.00M$6.30M$7.44M$9.32M$10.51M$12.30M
SG&A expense$5.15M$4.66M$4.26M$3.97M$3.54M$4.10M$4.96M$5.98M
Operating income-$12.12M-$12.06M-$11.26M-$17.61M-$10.98M-$13.42M$54.53M-$18.27M
Income tax—————$0$226,000—
Net income-$10.01M-$9.90M-$9.04M-$15.12M-$8.50M-$10.56M$56.54M-$15.98M
EBITDA-$12.09M-$12.03M-$11.23M-$17.54M-$10.89M-$13.33M$54.62M-$18.19M
EPS (basic)-0.17-0.17-0.16—-0.15-0.191.00—
EPS (diluted)-0.17-0.17-0.16—-0.15-0.190.98—
Weighted avg. shares (diluted)57.46M57.37M57.23M—56.93M56.80M57.67M—
Balance sheet
Cash & equivalents$15.08M$19.19M$30.07M$20.99M$30.86M$29.99M$98.42M$37.26M
Short-term investments$86.95M$91.31M$88.19M$107.66M$104.64M$112.84M$53.98M$62.14M
Current assets$106.54M$115.39M$122.97M$132.44M$138.99M$146.73M$155.68M$101.18M
PP&E, net$282,000$310,000$338,000$365,000$1.13M$1.21M$1.30M$1.39M
Total assets$115.56M$125.03M$132.92M$143.01M$157.73M$166.38M$176.25M$122.64M
Current liabilities$15.40M$15.84M$14.53M$15.73M$15.54M$16.80M$16.85M$20.57M
Total liabilities$27.48M$28.94M$28.62M$30.80M$31.58M$33.77M$34.73M$39.35M
Shareholders' equity$88.08M$96.09M$104.30M$112.21M$126.15M$132.61M$141.52M$83.28M
Shares outstanding57.47M57.45M57.30M57.14M56.94M56.89M56.68M56.64M
Cash flow statement
Operating cash flow-$8.34M-$7.97M-$10.23M-$6.79M-$7.85M-$9.16M$53.41M-$15.05M
Capital expenditure———————$0
Free cash flow———————-$15.05M
Investing cash flow$4.22M-$3.12M$19.50M-$2.89M$8.59M-$59.15M$8.55M$27.77M
Financing cash flow$12,000$217,000-$185,000-$196,000$134,000-$116,000$32,000$291,000
Depreciation & amortization$28,000$28,000$27,000$66,000$86,000$86,000$87,000$85,000
Stock-based compensation$2.23M$1.51M$1.45M$1.41M$1.74M$1.78M$1.70M$1.64M

Free plan shows the latest 8 periods; Pro shows all 35 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.